CurrentCignaPolicy N/A

Orencia (abatacept) subcutaneous prior authorization

This document is a Cigna prior authorization/coverage form for subcutaneous abatacept (Orencia) used for indications such as RA, PsA, pJIA, and GvHD; it governs prior authorization submission requirements for providers and affects Cigna members and prescribing clinicians.

Policy Summary

PayerCigna

PolicyOrencia (abatacept) subcutaneous prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionComplete and submit the prior authorization form with patient/provider details, medication selection, dose/quantity/duration, J‑code if applicable, and documentation of prior biologic/DMARD trials as required.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5 business daysstandard response time

855-840-1678fax

800-882-4462urgent phone

Listed biologics/DMARDscovered alternatives

Prior Authorization Coverage Criteria

Policy Summary

PayerCigna

PolicyOrencia (abatacept) subcutaneous prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Administrative and clinical submission requirements: Completed prior authorization form with patient and provider details, drug selection (including selected Orencia formulation), dose, quantity, duration, J-code if applicable, frequency, administration site/setting, and where medication will be obtained.

Form must include all asterisked/required items to receive a response; standard response time is 5 business days unless urgent.

Indication selection: Specify diagnosis: GvHD, polyarticular juvenile idiopathic arthritis (pJIA), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or other.

Certain indications require prescriber specialty or consultation confirmation (e.g., transplant center/oncologist for GvHD; rheumatologist for pJIA/PsA/RA).

New start vs continuation: Indicate whether this is a new start or continued therapy; if continuation, provide dates patient received Orencia and document whether there was a good response.

Continuation without demonstrated benefit requires clinical support. If patient has received samples, mark as new start per form instructions.

Required clinical and administrative information: Provide patient demographics (Cigna ID, DOB, weight), prescriber specialty/contact, clinical indication details, drug selection/strength, dose, frequency, duration, and administration site/setting.

Include prescriber signature/attestation and where medication will be obtained (site or specialty pharmacy).

Prior biologic and DMARD therapy documentation: Document prior and concurrent biologic and targeted/other DMARDs: list drug name and strength, dates taken, duration, documented response, and any intolerances or adverse reactions.

Form asks whether the patient is currently on other biologics and how the requested drug will be used in relation to them.

Indication-specific alternative therapy requirements: For pJIA, PsA, and RA provide documentation of trials of the listed covered alternative biologics or DMARDs (names, dates, duration, results, and intolerances); if alternatives were not tried, provide contraindication or clinical rationale.

For pJIA the form requests that the patient tried 2 or more alternatives when applicable. For PsA/RA, if no prior biologics, at least one conventional DMARD (e.g., methotrexate, leflunomide, sulfasalazine) should be documented or reasons for inability to try provided.

Per the form, infusion or administration of the requested medication must occur in the least intensive, medically appropriate setting when required by the member's plan. The form asks the provider to indicate the planned administration site (for example: home, physician's office, hospital outpatient, or other) and to state where the medication will be obtained (for example: Accredo Specialty Pharmacy, hospital outpatient, retail pharmacy, home infusion vendor, or physician office stock). Plan-specific network or site restrictions and pharmacy sourcing (including Cigna’s nationally preferred specialty pharmacy, Accredo) may apply.

Provider Submission Requirements and Actions

Prior Authorization

Prior Authorization Form Submission

A prior authorization form must be completed and submitted (fax or online) and must include medication selection, J-code if applicable, dose/quantity, frequency, duration of therapy, and supporting clinical documentation (patient demographics, Cigna ID, DOB, weight, diagnosis/indication, and prescribing clinician information). Save time by submitting online at www.covermymeds.com or via SureScripts in your EHR.

Include medication selection and formulation (e.g., Orencia 50mg, 87.5mg, 125mg syringe or ClickJect).
Provide J‑code when applicable and requested dose/quantity, frequency, and duration of therapy.
Supply patient demographics: full name, Cigna ID, date of birth, weight, address, and phone.
Provide prescriber information: physician name, specialty, DEA/NPI/TIN, office contact, phone and fax.

Denial Risk

Incomplete Form Risk

Incomplete or missing required fields (the form highlights certain items with an asterisk) — such as patient identifiers, Cigna ID, prescriber DEA/NPI/TIN, or required clinical fields — may prevent the plan from responding to the request and can delay or result in denial of coverage. Be sure all asterisked items and sections (including attestation and prescriber signature/date) are completed.

Incomplete asterisked patient/physician information may prevent a response to the request.
Attach clinical notes, prior medication history, and dates of prior therapies to avoid delays.

Documentation Required

Documented Trials of Alternatives Required

For pJIA, PsA, and RA indications the form requires documentation of trials of covered alternative biologics or DMARDs. For each alternative tried, provide drug name and strength, dates taken, duration, and documented results (including lack of efficacy or intolerances/adverse reactions). If an alternative was not tried, provide clinical justification (contraindication, FDA label warning, disease characteristic, inability to administer the alternative, or other reason).

pJIA alternatives: Actemra SQ, Enbrel, Humira, Orencia SQ — document trials (names, dates, duration, results) and indicate if patient tried ≥2 alternatives.
PsA alternatives: Cimzia, Cosentyx, Enbrel, Humira, Orencia SQ, Simponi SQ, Skyrizi, Stelara SQ, Taltz — document trials and reasons why any were not tried.
RA alternatives: Actemra SQ, Cimzia, Enbrel, Humira, Kevzara, Kineret, Orencia SQ, Simponi SQ — document trials and reasons why any were not tried.
If PsA or RA patient has not tried biologic/tsDMARDs, document trial of at least one DMARD (e.g., methotrexate, leflunomide, sulfasalazine) or provide reasons it cannot be tried.

Covered Alternatives and Definitions

Covered alternatives

pJIA covered alternativesActemra SQ; Enbrel; Humira; Orencia SQ — document drug name/strength, dates taken, duration, results, and intolerances.

RA covered alternativesActemra SQ; Cimzia; Enbrel; Humira; Kevzara; Kineret; Orencia SQ; Simponi SQ — document drug name/strength, dates taken, duration, results, and intolerances; if not tried, provide contraindication or clinical rationale.

PsA covered alternativesExamples include Actemra, Cimzia, Cosentyx, Enbrel, Humira, Simponi, Stelara, Taltz — document trials with dates, duration, response, and intolerances; indicate if additional biologic/tsDMARDs were tried (see form list).

GvHD considerationsWhen GvHD is selected, clinical questions include concurrent calcineurin inhibitor or methotrexate use, transplant donor type, and whether prescribing is by/with an oncologist/hematologist or transplant center; alternatives guidance is not specific but specialty consultation is required.

Documentation required for all alternativesFor each alternative tried include drug name and strength, date(s) taken, duration, documented results (efficacy) and any intolerances/adverse reactions; for alternatives not tried provide reasons (contraindication, label warnings, clinical factors, or administration limitations).

Drug Background

Orencia (abatacept) is a biologic disease‑modifying agent provided as a subcutaneous formulation for autoimmune conditions. The form lists indications including rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis, and also allows graft‑versus‑host disease as a potential diagnosis. For certain indications the form requests specialty prescriber involvement (for example, transplant center/oncologist for GvHD and rheumatologist for pJIA/PsA/RA) to ensure appropriate specialist oversight.

OpenPayer

Orencia (abatacept) subcutaneous prior authorization

Prior Authorization Coverage Criteria

Billing and Codes

Provider Submission Requirements and Actions

Covered Alternatives and Definitions

Drug Background